Skip to main content

Lansoprazole

FDA recalls

5 rows

DateCompany and reasonClass
Mar 22, 2022Dr. Reddy's Laboratories, Inc.
Failed Dissolution Specifications; during long term stability testing.
Class II · Terminated
Dec 2, 2020Zydus Pharmaceuticals (USA) Inc
Failed Dissolution Specifications
Class II · Terminated
Oct 26, 2020Zydus Pharmaceuticals (USA) Inc
Failed Dissolution Specification
Class II · Terminated
Mar 10, 2019Teva Pharmaceuticals USA
Subpotent Drug.
Class III · Terminated
Jan 29, 2013Mylan Pharmaceuticals Inc.
Presence of Foreign Tablets/Capsules: Bottles of lansoprazole 30 mg delayed-release capsules may contain topiramate 100 mg tablets.
Class II · Terminated

← Back to Lansoprazole

Sources: CMS Medicare Part D Prescribers 2024; CMS Open Payments 2025 (general payments; a payment is not evidence of wrongdoing); FDA enforcement reports (openFDA).